← Back to Search

Low Vision Aids for Glaucoma (LOVIT Trial)

N/A
Waitlist Available
Led By Cindy ML Hutnik, Bsc(Hon), MD, PhD, FRCSC
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
No Placebo-Only Group

Summary

Our team is interested in what can be done to improve the functioning of patients who suffer from glaucoma, a chronic and irreversible eye disease. Patients with vision loss as a result of this disease may feel like they have been 'given up on', or lost to our medical system when no further interventions can be offered to treat their eye disease. It is our intent to investigate what alternatives we can provide our patients, instead of simply saying, 'nothing more can be done'. We have learned from studies done on other chronic eye diseases, like age related macular degeneration, that low vision rehabilitation can improve visual function. What exactly is low vision? It can involve a loss of visual acuity, making activities such as reading or writing a challenge; it can involve loss of contrast sensitivity, making shapes and edges hard to discern, like those of a stair edge, or person's face. It could also involve a loss of peripheral, or side vision which is a symptom common to most glaucoma patients. Whatever the cause of low vision, doing day-to-day activities can become increasingly difficult, and many suffer from a loss of their independence and may even become depressed. Low vision rehabilitation involves helping patients to use their remaining vision in optimal, and sometimes even new, ways. This involves an assessment of a person's baseline vision, and an idea of what their needs are. Patients are then given low vision aids (such as magnifiers, telescopes, video screens which magnify images, and other tools) as well as instructions and support for adapting to living and functioning with altered vision. Although there currently exists no cure for glaucoma, and we are certainly not promising a reversal of the damage done to the eyes from this chronic disease, we do believe that these types of rehabilitation services may offer some hope and potential visual benefit to patients living with vision loss. Our hypothesis is that the use of state-of-the-art low vision aids in patients with advanced glaucomatous visual loss will provide an improvement in visual tasks and thereby an improvement in quality of life.

Eligible Conditions
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Visual reading ability and visual mobility.
Secondary study objectives
Other visual ability domains.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Low Vision AidsExperimental Treatment3 Interventions
All patients will receive: 1. A low vision examination: 1. Low vision refraction 2. Distance best corrected visual acuity 3. Near best corrected visual acuity 4. Contrast Sensitivity 5. Quality of life questionnaire 2. Low vision therapy: to teach strategies for more effective use of remaining vision and use of low-vision devices 3. Prescribed low vision devices including binocular telescope (2.1x or 3.5x), monocular telescope, 6x telemicroscopes, microscopes, magnifiers, portable CCTV and absorptive filters.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
portable CCTV
2011
N/A
~20
Telescopes, telemicroscopes and microscopes
2011
N/A
~20
Absorptive filters
2011
N/A
~20

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
680 Previous Clinical Trials
421,917 Total Patients Enrolled
6 Trials studying Glaucoma
592 Patients Enrolled for Glaucoma
PfizerIndustry Sponsor
4,660 Previous Clinical Trials
17,877,311 Total Patients Enrolled
25 Trials studying Glaucoma
4,333 Patients Enrolled for Glaucoma
Cindy ML Hutnik, Bsc(Hon), MD, PhD, FRCSCPrincipal InvestigatorIvey Eye Institute
~1 spots leftby Nov 2025